Resverlogix

Resverlogix Forward P/E

The Forward P/E Ratio of Resverlogix (RVX.TO) as of Oct 25, 2026 is -2.54. In the previous year, Forward P/E Ratio was -3.72 — a change of -31.88% (higher).

Forward P/E

-2.54

YoY

-31.88%

Last updated:

Forward P/E Ratio of Resverlogix is 2025 -2.54 . Forward P/E Ratio of Resverlogix was 2024 -3.72 . It decreases by -31.88% higher compared to the previous year.

The Resverlogix Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
-123.11 USD
Jan 1, 2019
0.17 USD
Jan 1, 2020
8,132.57 USD
Jan 1, 2021
-0.81 USD
Jan 1, 2022
-7.87 USD
Jan 1, 2023
-1.70 USD
Jan 1, 2024
-3.72 USD
Jan 1, 2025
-2.54 USD
The Resverlogix Forward P/E history
YEARForward P/EYoY
-2.54-31.88%
-3.72+119.27%
-1.70-78.44%
-7.87+873.20%
-0.81-100.01%
8,132.57+4.79 M%
0.17-100.14%
-123.11+35,717.39%
-0.34-20.75%
-0.43-57.34%
-1.02-192.94%
1.09—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resverlogix Stock analysis

What does Resverlogix do? Resverlogix Corp is a biopharmaceutical company based in Canada that specializes in the research and development of innovative therapies for cardiovascular diseases. It was founded in 2001 by Dr. Donald J. McCaffrey and has been listed on the Toronto Stock Exchange since 2006. The company focuses on the development of synthetic molecules with the same potential as Resveratrol, a natural compound found in red grapes and wine, for the treatment of cardiovascular diseases. Resverlogix Corp follows an innovative business model that involves identifying disease-causing factors and developing targeted molecules to influence them, with the goal of developing effective therapies for patients with cardiovascular diseases. The company specializes in the development of therapeutic agents for atherosclerosis and diabetic nephropathy, and currently has two main products in clinical development: Apabetalone for the treatment of atherosclerosis and BAC25 for diabetic nephropathy. Apabetalone acts directly on the genome of cells and influences the gene expression of proteins relevant to the development of atherosclerosis, while BAC25 targets glucose and lipid metabolism in the kidney to slow down or prevent the development of diabetic nephropathy. Overall, Resverlogix Corp is a biopharmaceutical company focused on innovative therapies for cardiovascular diseases, with a business model based on identifying disease-causing factors and developing synthetic molecules to target them. Resverlogix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resverlogix stock

Forward P/E Ratio of Resverlogix is -2.54 in 2025.

Forward P/E Ratio of Resverlogix changed from -3.72 to -2.54, representing a -31.88% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Resverlogix since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Resverlogix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Resverlogix

All Key Metrics — Resverlogix